Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel

• Partnership includes future commercialization of NeuVax(TM) in Israel and financial support
• Key clinical sites approved and established in Israel for PRESENT Phase 3 trial

LAKE OSWEGO, Ore., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (GALE), a biotechnology company focused on developing innovative, targeted oncology treatments, today announced it has signed an agreement with a subsidiary of Teva Pharmaceutical Industries Limited for the commercialization of NeuVax(TM) (nelipepimut-S or E75) in Israel.

Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine Businesses

Transaction Will Add Breakthrough Biologics Platform and Pipeline to Further Accelerate Growth Opportunities in Wright’s Extremities Business

Upfront Purchase Price Payment of $190 Million in Cash and Stock Plus Contingent Payments of up to $190 Million

Wright Medical Group, Inc. (WMGI) and BioMimetic Therapeutics, Inc. (BMTI) announced today that they have entered into a definitive agreement for a business combination of Wright and BioMimetic, both publicly traded, Tennessee-based companies.

Tiny Tekmira Lands $65M Settlement Plus $10M in Near-Term Milestone Payments from Alnylam

On the eve of their transformational legal trial, emerging developer Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO) announced after the market close on Monday that they had settled all litigation matters between the firm and Alnylam Pharmaceuticals, Inc. (ALNY) - whose shares dropped -4.23% After Hours to $15.44 on the news.

Tekmira, which closed Monday`s session with a $70M market cap will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013.

Galena Biopharma Reports Third Quarter 2012 Financial Results

Galena Biopharma, Inc. (GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today reported its financial results for the quarter ended September 30, 2012 and provided a business update.

"We have made significant progress in accelerating patient enrollment in the NeuVax(TM) Phase 3 PRESENT trial," said Mark J. Ahn, Ph.D., President and Chief Executive Officer. "We have strengthened our team and intellectual property, and have opened 40 sites in North America and started opening an additional 40 sites in Western and Eastern Europe, Russia, Ukraine and Israel as planned. 2013 will be a significant year of operational and business development milestones for the company."